Sequent Scientific Limited

NSE SEQUENT.NS

Sequent Scientific Limited Revenue Per Share for the year ending March 31, 2024: USD 0.66

Sequent Scientific Limited Revenue Per Share is USD 0.66 for the year ending March 31, 2024, a -5.49% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Sequent Scientific Limited Revenue Per Share for the year ending March 31, 2023 was USD 0.70, a -7.31% change year over year.
  • Sequent Scientific Limited Revenue Per Share for the year ending March 31, 2022 was USD 0.75, a 0.37% change year over year.
  • Sequent Scientific Limited Revenue Per Share for the year ending March 31, 2021 was USD 0.75, a 18.23% change year over year.
  • Sequent Scientific Limited Revenue Per Share for the year ending March 31, 2020 was USD 0.63, a 4.59% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
NSE: SEQUENT.NS

Sequent Scientific Limited

CEO Mr. Rajaram Narayanan
IPO Date March 10, 2016
Location India
Headquarters Dosti Pinnacle
Employees 1,195
Sector Health Care
Industries
Description

Sequent Scientific Limited engages in the animal health business worldwide. The company provides animal health active pharmaceutical ingredients (APIs) and finished dosage formulations in the areas of feed supplements, antibiotics, anthelmintics, antibacterial, anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It offers analytical solutions that supports API, pharmaceutical, personal care, and nutraceutical organizations, as well as provides method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs and Pharmaceuticals Limited and changed its name to Sequent Scientific Limited in October 2009. Sequent Scientific Limited was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited operates as a subsidiary of CA Harbor Investments.

Similar companies

SYNGENE.NS

Syngene International Limited

USD 9.56

0.73%

SOLARA.NS

Solara Active Pharma Sciences Limited

USD 7.64

4.37%

INDOCO.NS

Indoco Remedies Limited

USD 3.76

0.04%

LAURUSLABS.NS

Laurus Labs Limited

USD 6.56

1.75%

HIKAL.NS

Hikal Limited

USD 4.21

4.98%

StockViz Staff

January 15, 2025

Any question? Send us an email